Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Thakur, Archana ^a,b   Schalk, Dana ^a   Tomaszewski, Elyse ^a   Kondadasula, Sri V ^a   Yano, Hiroshi ^a   Sarkar, Fazlul H ^b   Lum, Lawrence G ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

3D culture model; Activated T cells; Bispecific antibody; Epidermal growth factor receptor; Myeloid derived suppressor cells; Pancreatic cancer

Indexed keywords

ARGINASE 1; BISPECIFIC ANTIBODY; CD33 ANTIGEN; CXCL9 CHEMOKINE; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMCITABINE; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; L SELECTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PROSTAGLANDIN E2; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL KILLING; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME REGULATION; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MICROENVIRONMENT; MYELOID DERIVED SUPPRESSOR CELL; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TH1 CELL;

CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84873462951     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-35     Document Type: Article

References (47)

1. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008, 222:162-179. 10.1111/j.1600-065X.2008.00602.x, 18364001.
2. Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells. J Immunol 2010, 184:3106-3116. 10.4049/jimmunol.0902661, 2832724, 20142361.
3. Katamura K, Shintaku N, Yamauchi Y, Fukui T, Ohshima Y, Mayumi M, Furusho K. Prostaglandin E(2) at Priming of Naive Cd4(+) T-Cells Inhibits Acquisition of Ability to Produce Ifn-Gamma and Il-2, But Not Il-4 and Il-5. J Immunol 1995, 155:4604-4612.
4. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8(+) T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004, 172:989-999.
5. Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8(+) T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005, 175:4583-4592. 1350970, 16177103.
6. Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, Hayakawa Y, Godfrey DI, Ostrand-Rosenberg S, Smyth MJ, Berzofsky JA. A non-classical type IINKT cell suppresses tumor immunity. J Immunol 2006, 176:S274.
7. Eruslanov E, Kaliberov S, Daurkin I, Kaliberova L, Buchsbaum D, Vieweg J, Kusmartsev S. Altered Expression of 15-Hydroxyprostaglandin Dehydrogenase in Tumor-Infiltrated CD11b Myeloid Cells: A Mechanism for Immune Evasion in Cancer. J Immunol 2009, 182:7548-7557. 10.4049/jimmunol.0802358, 19494278.
8. Eruslanov E, Daurkin I, Vieweg J, Daaka Y, Kusmartsev S. Aberrant PGE(2) metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells. Int Immunopharmacol 2011, 11:848-855. 10.1016/j.intimp.2011.01.033, 3241976, 21315786.
9. Legler DF, Bruckner M, Uetz-von Allmen E, Krause P. Prostaglandin E(2) at new glance: Novel insights in functional diversity offer therapeutic chances. Int J Biochem Cell Biol 2010, 42:198-201. 10.1016/j.biocel.2009.09.015, 19788928.
10. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007, 67:4507-4513. 10.1158/0008-5472.CAN-06-4174, 17483367.
11. Veltman JD, Lambers MEH, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JGJV, Hegmans JPJJ. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 2010, 10:464-476. 10.1186/1471-2407-10-464, 2939552, 20804550.
12. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007, 13:721S-726S. 10.1158/1078-0432.CCR-06-2197, 17255300.
13. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007, 109:1568-1573. 10.1182/blood-2006-06-031856, 1794048, 17023580.
14. Thakur A, Schalk D, Al-Khadimi Z, Sarkar F, Lum L. A Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells. Cancer Immunol Immunother 2012, 61:497-509. 10.1007/s00262-011-1116-1, 21971587.
15. Sen M, Wankowski DM, Garlie NK, Siebenlist RE, Van Epps D, LeFever AV, Lum LG. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu Tumors. J Hematother Stem Cell Res 2001, 10:247-260. 10.1089/15258160151134944, 11359672.
16. Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res 2006, 12:569-576. 10.1158/1078-0432.CCR-05-2005, 16428502.
17. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4(+) and CD8(+) T Cells. J Immunol 2009, 183:937-944. 10.4049/jimmunol.0804253, 2800824, 19553533.
18. Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Positive feedback between PGE(2) and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011, 118:5498-5505. 10.1182/blood-2011-07-365825, 3217352, 21972293.
19. Rodriguez PC, Zea AH, Zabaleta J, Ochoa JB, Ochoa AC. L-Arginine consumption by macrophages modulates the expression of T cell receptor CD3Z chain in T lymphocytes. J Immunother 2003, 26:S28.
20. Rodriguez PC, Ochoa AC. T cell dysfunction in cancer: Role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Semin Cancer Biol 2006, 16:66-72. 10.1016/j.semcancer.2005.10.001, 16298138.
21. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444. 10.1038/nature07205, 18650914.
22. Ostrand-Rosenberg S, Sinha P. Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer. J Immunol 2009, 182:4499-4506. 10.4049/jimmunol.0802740, 2810498, 19342621.
23. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 2006, 176:284-290.
24. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007, 67:10019-10026. 10.1158/0008-5472.CAN-07-2354, 17942936.
25. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000, 18:245-273. 10.1146/annurev.immunol.18.1.245, 10837059.
26. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of Monocytes, Macrophages, and Dendritic Cells. Science 2010, 327:656-661. 10.1126/science.1178331, 2887389, 20133564.
27. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005, 115:1-20. 10.1111/j.1365-2567.2005.02143.x, 1782125, 15819693.
28. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappa B signal. Immunity 1998, 8:297-303. 10.1016/S1074-7613(00)80535-X, 9529147.
29. Yeh WC, Shahinian A, Speiser D, Kraunus J, Billia F, Wakeham A, DelaPompa JL, Ferrick D, Hum B, Iscove N, Ohashi P, Rothe M, Goeddel DV, Mak TW. Early lethality, functional NF-kappa B activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 1997, 7:715-725. 10.1016/S1074-7613(00)80391-X, 9390694.
30. Vallabhapurapu S, Karin M. Regulation and Function of NF-kappa B Transcription Factors in the Immune System. Annu Rev Immunol 2009, 27:693-733. 10.1146/annurev.immunol.021908.132641, 19302050.
31. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9:361-371. 10.1038/nrc2628, 19343034.
32. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174. 10.1038/nri2506, 2828349, 19197294.
33. Gabrilovich DI. Myeloid-derived Suppressor Cells and Tumor Microenvironment. J Immunother 2009, 32:987-988.
34. Nagaraj S, Gabrilovich DI. Myeloid-Derived Suppressor Cells in Human Cancer. Cancer J 2010, 16:348-353. 10.1097/PPO.0b013e3181eb3358, 20693846.
35. Kalinski P, Hilkens C, Schuitemaker J, Snijders A, Kapsenberg M. CD1a(+)CD83(+) DC, which mature in the absence or in the presence of PGE(2). Promote Th1 versus Th2 responses. J Invest Dermatol 1997, 109:27.
36. Kalinski P, Hilkens CMU, Snijders A, Snijdewint FGM, Kapsenberg ML. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E-2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol 1997, 159:28-35.
37. Kalinski P, Schuitemaker JHN, Hilkens CMU, Kapsenberg ML. Prostaglandin E-2 induces the final maturation of IL-12-deficient CD1a(+)CD83(+) dendritic cells: The levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol 1998, 161:2804-2809.
38. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3 chain expression by L-arginine. J Biol Chem 2002, 277:21123-21129. 10.1074/jbc.M110675200, 11950832.
39. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC. Arginase I-Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes. Cancer Res 2009, 69:1553-1560. 10.1158/0008-5472.CAN-08-1921, 2900845, 19201693.
40. Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood 2011, 117:5381-5390. 10.1182/blood-2010-11-321752, 3109712, 21450901.
41. Kuroda E, Sugiura T, Okada K, Zeki K, Yamashita U. Prostaglandin E-2 up-regulates macrophage-derived chemokine production but suppresses IFN-Inducible protein-10 production by APC. J Immunol 2001, 166:1650-1658.
42. Muthuswamy R, Kalinski P, Reinhart T, Schadendrof D. PGE2 Transiently Enhances DC Expression of CCR7 but Inhibits the Ability of DCs to Produce CCL19 and Attract Naive T cells. Clin Immunol 2010, 135:S100.
43. Sharma S, Stolina M, Yang SC, Baratelli F, Lin JF, Atianzar K, Luo J, Zhu L, Lin Y, Huang M, Dohadwala M, Batra RK, Dubinett SM. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 2003, 9:961-968.
44. Takayama K, Garcia-Cardena G, Sukhova GK, Comander J, Gimbrone MA, Libby P. Prostaglandin E-2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 2002, 277:44147-44154. 10.1074/jbc.M204810200, 12215436.
45. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, Ohlfest JR, Okada H. COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells. Cancer Res 2011, 71:2664-2674. 10.1158/0008-5472.CAN-10-3055, 3075086, 21324923.
46. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE(2)-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment. Cancer Res 2011, 71:7463-7470. 10.1158/0008-5472.CAN-11-2449, 22025564.
47. Samarasinghe S, Mancao C, Pule M, Nawroly N, Karlsson H, Brewin J, Openshaw P, Gaspar HB, Veys P, Amrolia PJ. Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy. Blood 2010, 115:396-407. 10.1182/blood-2009-08-235895, 19890093.